Stekhoven, D., Scherer, A., Nissen, M.J. et al.: Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin Rheumatol (2017), doi:10.1007/s10067-017-3637-2, 22 April 2017
Chaigne B et Finckh A et al: Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Qual Life Res. 2017 Mar 11. doi: 10.1007/s11136-017-1534-4. [Epub ahead of print]
Chatzidionysiou K and Gabay C et al: Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15.
Iannone F and Finckh A et al: Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2016 Dec 14. PMID: 27966068 DOI: 10.1007/s10067-016-3505-5 [Epub ahead of print]
Mueller RB et al, “Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)”. Clin Rheumatol. 2016 Nov 12. [Epub ahead of print]
Nissen MJ et al: “The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.” Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691.
Courvoisier DS and Finckh A et al. “Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.” EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024.
Gottenberg JE and Finckh A et al., "Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis", Arthritis Rheumatology 2016, 68(6): 1346-52.
Mercer LK and Finckh A et al., "Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 Eurpean biologics registers", Ann Rheum Dis 2016 [Epub ahead of print].
Katerina Chatzidionysiou, Cem Gabay et al, “Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration” Arthritis Res Ther. 2016; 18: 50. Published online 2016 Feb 16.
Adrian Ciurea et al., "Does the reason for discontinuation of a firt TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort", Arthritis Research & Therapy 2016, 18:71.
Axel Finckh et al., "The impact of patient heterogeneity and socio-economic factors across nine European countries on abatacept retention in rheumatoid arthritis". RMD Open. 2015 Apr 30;1(1): PMID: 26509062.